SecBot SecBot
424B5 ·Filed Apr 13, 2026

SYRE

Spyre Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001628280-26-024940
Notable filing: 424B5
Actionable Insight ▲ Bullish

The offering follows positive clinical data, suggesting confidence in the pipeline. The substantial capital raise combined with strong cash position provides runway for multiple clinical programs. Traders should monitor enrollment in Part B of the SKYLINE trial and upcoming data readouts for SPY002 and SPY003.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$64.01
T+0 close · Apr 13, 2026 · via day close
Latest settled
+54.27%
T+60 · $98.75
Vs SPY
+45.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $64.01entry
  2. T+1 · 7mo ago +7.78%α +7.01% · $68.99
  3. T+5 · 7mo ago +11.34%α +9.95% · $71.27
  4. T+20 · 6mo ago +19.40%α +13.11% · $76.43
  5. T+60 · 4mo ago +54.27%α +45.75% · $98.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics is raising $300 million through a common stock offering, following positive Phase 2 topline data for its lead candidate SPY001 in ulcerative colitis. The company reported preliminary cash of $741 million as of March 31, 2026, and has terminated its prior ATM offering. The capital will fund ongoing clinical programs in inflammatory bowel and rheumatic diseases.

Key Facts

  • Spyre Therapeutics is offering $300 million of common stock
  • Positive Phase 2 topline data for SPY001 in ulcerative colitis showed statistically significant reduction in RHI score of 9.2 points (p<0.0001)
  • Company reported preliminary cash of $741 million as of March 31, 2026
  • Terminated prior ATM offering in connection with this new offering
  • Proceeds will fund clinical programs in IBD and rheumatic diseases
  • Stock priced at $51.29 per share on April 10, 2026, prior to announcement

Financial Impact

Raises $300 million in gross proceeds, with net proceeds to be used for advancing clinical programs. Company had $741 million in cash as of March 31, 2026.

cashdilutiondilution

Risk Factors

  • Dilution to existing shareholders from the $300 million offering
  • Clinical trial risks for ongoing and future studies
  • Competition in the IBD and rheumatic disease markets

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001628280-26-024940
Document: 0001628280-26-024940-index-headers.html0001628280-26-024940
Document: 0001628280-26-024940-index.html0001628280-26-024940
Document: 0001628280-26-024940.txt0001628280-26-024940

Track record

36 reports on SYRE

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +50.78% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026